By Faith Ashmore, Benzinga
Solid tumors are abnormal clumps of cells that form in various tissues or organs of the body. Unlike liquid or cystic tumors, solid tumors do not contain any liquid components. They can occur in bones, muscles and organs, and can be either benign or malignant. Solid tumors can arise from different types of cells, such as epithelial cells that line the outer surface of the skin and the covering and lining of organs and internal passageways.
Solid tumors are generally considered more aggressive and difficult to treat compared to other types of tumors. This is because they have a tendency to grow, invade nearby tissues, and metastasize to other parts of the body. The characteristics that make solid tumors more challenging to treat include their ability to resist traditional cancer treatments such as chemotherapy and radiation therapy and their complex genetic makeup, which can vary from patient to patient. Additionally, the location of solid tumors within the body can also contribute to treatment difficulties, as certain areas may be more difficult to access or treat effectively.
In order to improve treatment outcomes for solid tumors, researchers and medical professionals are continuously exploring new therapeutic approaches and personalized treatments tailored to the specific characteristics of each tumor. By gaining a better understanding of the underlying biology and genetic abnormalities of individual solid tumors, targeted therapies can be developed to selectively attack cancer cells while minimizing damage to healthy tissues.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is a biopharmaceutical company focused on the development of innovative treatments for cancer, with a particular emphasis on solid tumors. The primary product being developed by Oncotelic, through its joint venture is OT-101, also known as Trabedersen. OT-101 is a novel antisense oligodeoxynucleotide designed to target transforming growth factor beta 2 (TGF-2) overexpression in various malignancies, including pancreatic carcinoma, malignant melanoma, colorectal carcinoma and high-grade glioma. Oncotelic aims to address the aggressive nature of solid tumors and their resistance to conventional treatments.
In April 2022, Oncotelics joint venture (JV) with Dragon Overseas Capital Limited, an affiliate of Golden Mountain Partners, LLC. The JV initial focus is on the development and commercialization of OT-101, the transformative cancer drug that Oncotelic licensed to the JV for a 45% ownership. Dragon Overseas invested cash of $27.6 million for a 55% ownership of the JV.
The JV is planned to be headquartered in Hong Kong. Oncotelic could potentially receive up to $50 million following the sale of the RPD voucher once OT-101 has received marketing approval for diffuse intrinsic pontine gliomas. The JV is expected to launch an initial public offering (IPO) on the Hong Kong Stock Exchange in 2024, and CEO Dr. Vuong Trieu has said he expects the IPO to be highly successful.
I am excited to announce that, together with our partner Dragon Overseas, we have formed a JV for the discovery, development, and commercialization of TGF- therapeutics against all pharmaceutical indications, said Dr. Vuong Trieu, CEO and Chairman of Oncotelic. This JV unburdens the Company of the high cost of drug development, which the JV will be responsible for, while the Company will participate in its upside through appreciation in the value of its shares in the JV.
The solid tumors market was valued at $209.61 billion in 2021, and it's expected to reach $901.27 billion by 2029. Oncotelic's focus on developing therapies specifically for solid tumors puts them in a very strong position to be a leader in a growing market. The company's research and development efforts in this area demonstrate its commitment to bringing fresh energy and potential breakthroughs into the treatment of solid tumors, offering new possibilities for patients.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
View source version on newsdirect.com: https://newsdirect.com/news/the-solid-tumors-market-is-expected-to-be-worth-901-27-billion-by-2029-and-oncotelic-therapeutics-otcqb-otlc-is-leading-the-charge-977974550
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No News Feed Central journalist was involved in the writing and production of this article.